Eastern Time (US & Canada) March 25, 2019, Cellular Biomedicine Group Inc. (Nasdaq: CBMG) successfully closed an underwritten public offering of its common stock (“Offering”).
Cantor Fitzgerald & Co. and Robert W. Baird & Co. Incorporated served as joint book-running managers and underwriters for the Offering. Guantao acted as the legal adviser to both underwriters in relation to the laws of People’s Republic of China.
Cellular Biomedicine Group, Inc. listed on The Nasdaq Global Market is a biopharmaceutical company engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases.
Guantao team was led by Hong Kong office managing partner Grace Pengpeng YAN and Yan RONG.